Ulcerative colitis: Current medical therapy and strategies for improving medication adherence

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 1, 2009, Pages 1-8

  Zhang, Zunwu ^a   Kennedy, Hugh ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Adherence; Aminosalicylates; Inflammatory bowel disease; Medical therapy; Self management; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; TACROLIMUS;

CLINICAL TRIAL; COLONOSCOPY; CONTINUOUS INFUSION; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; RECURRENCE; REMISSION INDUCTION; TREATMENT REFUSAL;

EID: 58149216528     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830bfb88     Document Type: Review

References (100)

1. Silverberg MS, Satsangi J, Ahmad T, Amott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A):5-36.
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369:1627-1640.
3. Carter MJ, Lobo AJ, Travis SP. IBD Section BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl 5):V1-16.
4. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. For the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis; definitions and diagnosis. J Crohn's Colitis 2008; 2:1-23.
5. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006; 82:332-337.
6. Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, et al Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21:1772-1782.
7. Wang Y, Ouyang Q. APDW 2004 Chinese IBD working group. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol 2007; 22:1450-1455.
8. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand PJ, Finkelstein JA. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5:1424-1429.
9. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. The DCCD study group. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-1282.
10. Niv Y, Abuksis G, Fraser GM. Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 2000; 95:693-698.
11. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, Van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39:690-697.
12. Frangos CC, Frangos CC. Inflammatory bowel disease: reviewing an old study under a new perspective. Gut 2007; 56:1638-1639.
13. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12:6102-6108.
14. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002; 97:1994-1999.
15. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53:1471-1478.
16. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. European Collaborative Study Group of Inflammatory Bowel Disease (EC-IBD). Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102:1692-1701.
17. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107:3-11.
18. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31:260-266.
19. Rutter M, Saunders B, Wilkinson K. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 118:671-674.
20. Höie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. European Collaborative Study Group of Inflammatory Bowel Disease. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132:507-515.
21. Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133:1779-1786.
22. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371-1385.
23. Travis SPL, Stange EF, Lémann M, Øresland T, Bemelman WA, Chowers Y, et al. For the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008; 2:24-62.
24. Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis 2007; 13:1293-1298.
25. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23:577-585.
26. Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007; 13 (7 Suppl A):S2-S12.
27. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96:2929-2933.
28. Cervený P, Bortlik M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13:1244-1249.
29. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Dohen A, Dobkin PL. Patient non-adherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98:1535-1544.
30. Stone MA, Mayberry J, Baker R. Prevalence and management of inflammatory bowel disease: a cross sectional survey from central England. Eur J Gastroen Hepat 2003; 15:1275-1281.
31. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94:1733-1742.
32. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:191-198.
33. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43.
34. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-1048.
35. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92:1894-1898.
36. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine FJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132:763-786.
37. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008; 27 (Suppl 1):15-21.
38. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17:29-42.
39. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; (3):CD000543. Update in: Cochrane Database Syst Rev 2006; (2): CD000543.
40. Kesisoglou F, Zimmermann EM. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2005; 2:451-463.
41. Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005; 57:281-302.
42. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut 2005; 54:960-965.
43. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867-1871.
44. Kam L, Cohen H, Dooley C, Rubin P, Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996; 91:1338-1342.
45. Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15:251-256.
46. Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, et al. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis 2002; 34:787-793.
47. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27 (Suppl 1):9-14.
48. Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther 2008; 27 (Suppl 1):1-8.
49. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21:827-834.
50. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006; 24 (Suppl 3):37-40.
51. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100:2478-2485.
52. D'Haens G, Hommes D, Engels L, Baert F, Van der Waaij L, Connor P, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006; 24:1087-1097.
53. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95-102.
54. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26:205-215.
55. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132:66-75.
56. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24:319-330.
57. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260.
58. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infl iximab in infl ammatory bowel disease. Gastroenterology 2006; 130:940-987.
59. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110:1416-1421.
60. Chande N, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 4:CD006618.
61. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; 4:CD000544. Review. Update in: Cochrane Database Syst Rev 2006; 2:CD000544.
62. Orchard T, Probert CS, Keshav S. Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2006; 24 (Suppl 1):17-22.
63. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
64. LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother 2004; 18:81-87.
65. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
66. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000; 18:48-90.
67. Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002; 16:1889-1893.
68. Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23:841-855.
69. Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51:2165-2169.
70. Cerveny P, Bortlik M, Kubena A, Lukás M. Nonadherence to treatment in inflammatory bowel disease in Czech Republic. J Crohn's Colitis 2007; 1:77-81.
71. López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 (Suppl 3):45-49.
72. Aliotta SL, Vlasnik JJ, Delor B. Enhancing adherence to long-term medical therapy: a new approach to assessing and treating patients. Adv Ther 2004; 21:214-231.
73. Aliotta SL, Boling J, Commander C, Day D, Greenberg L, Lattimer C, et al. The impact of CMSA's case management adherence guidelines and guidelines training on case manager-reported behavior change. Prof Case Manag 2007; 12:288-295.
74. Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000; 9 (9 Suppl):7-12.
75. Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet 2002; 359:2129-2130.
76. Kane SV. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008; 14:S2-S12.
77. Hall NJ, Rubin GP, Hungin AP, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol 2007; 7:20.
78. Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann Pharmacother 2008; 42:265-269.
79. D'Incà R, Bertomoro P, Mazzocco K, Vettorato MG, Rumiati R, Sturniolo GC. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008; 27:166-172.
80. Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102:1417-1426.
81. Martin A, Leone L, Castagliuolo I, DiMario F, Naccarato R. What do patients want to know about their inflammatory bowel disease? Ital J Gastroenterol 1992; 24:477-480.
82. Robinson A, Thompson DG, Wilkin D, Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001; 358:976-981.
83. Kennedy AP, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004; 53:1639-1645.
84. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13:373-379.
85. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973; 14:923-926.
86. Moshkovska T, Mayberry JF. Duration of treatment with 5-aminosalicylic acid compounds. World J Gastroenterol 2007; 13:4310-4315.
87. Coulter A. Paternalism or partnership. Br Med J 1999; 319:719-720.
88. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr 2007; 12 (8 Suppl 13):1-27.
89. Day JL. Diabetic patient education: determinants of success. Diabetes/Metab Res Rev 2000; 16 (Suppl 1):70-74.
90. Clark NM, Gong M, Schork MA, Evans D, Roloff D, Hurwitz M, et al. Impact of education for physicians on patient outcomes. Pediatrics 1998; 101:831-836.
91. Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, et al. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centered consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol Assess 2003; 7:1-113.
92. Osman L. Guided self-management and patient education in asthma. Br J Nurs 1996; 5:785-789.
93. Benbassat J, Pilpel D, Tidhar M. Patients' preferences for participation in clinical decision making: a review of published surveys. Behav Med 1998; 24:81-88.
94. Woodcock A, Kinmonth AL, Campbell MJ, Griffin S, Spiegal N. Diabetes care from diagnosis: effects of training in patient-centred care on beliefs, attitudes and behaviour of primary care professionals. Patient Educ Couns 1999; 37:65-79.
95. Kennedy AP, Rogers A. Improving patient involvement in chronic disease management: the views of patients, GPs and specialists on a guidebook for ulcerative colitis. Patient Educ Couns 2002; 47:257-263.
96. Guadagnoli E, Ward P. Patient participation in decision-making. Social Sc Med 1998; 47:329-339.
97. Thorne SE, Paterson BL. Health care professional support for self-care management in chronic illness: insights from diabetes research. Patient Educ Couns 2001; 42:81-90.
98. Dixon-Woods M. Writing wrongs? An analysis of published discourses about the use of patient information leaflets. Social Sc Med 2001; 52:1417-1432.
99. Cross RK, Finkelstein J. Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study. Dig Dis Sci 2007; 52:357-364.
100. Márquez-Contreras E, Martell-Qaros N, Gil-Guillén V, De la Figuera-Von Wichmann M, Casado-Martínez JJ, Martin-de Pablos JL, et al. Compliance Group of the Spanish Society of Hypertension (SEE). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: The EAPACUM-HTA Study. J Hypertens 2006; 24:169-175.